Lipid Panel on TRT: What Your Labs Mean and How to Interpret Them

Why a Lipid Panel Belongs in Every TRT Monitoring Schedule

A lipid panel is not optional when managing testosterone replacement therapy. TRT alters lipoprotein metabolism in measurable ways, and those changes interact directly with pre-existing cardiovascular risk factors. The Endocrine Society's 2018 clinical practice guideline recommends obtaining a fasting lipid panel before initiating TRT and repeating it at least annually thereafter, with more frequent checks after any dose change [1].

The mechanism is partly androgenic. Testosterone increases hepatic lipase activity, which accelerates the catabolism of HDL particles. It also stimulates erythropoiesis, and the resulting rise in hematocrit can increase blood viscosity independent of cholesterol, compounding vascular strain. A 2010 meta-analysis in the Journal of Clinical Endocrinology and Metabolism (24 RCTs, N=1,685) found that testosterone administration reduced HDL cholesterol by a mean of 0.49 mmol/L (roughly 19 mg/dL) compared with placebo [2]. That is a meaningful change for a patient who starts therapy with an HDL of 45 mg/dL.

Delivery method matters as much as dose. Intramuscular injections of testosterone cypionate or enanthate produce larger, sharper testosterone peaks, and peak supraphysiologic levels correlate with more pronounced HDL suppression than the steadier levels seen with transdermal gels or subcutaneous pellets [3]. Knowing this helps explain why two men on the same weekly dose can show very different lipid panels six months into therapy.

What a Normal Lipid Panel Looks Like, and How TRT Shifts Each Marker

HDL Cholesterol

HDL is the marker most consistently affected by TRT. Short answer: it goes down, and the degree of suppression predicts cardiovascular risk better than any other lipid change on therapy.

The American Heart Association defines optimal HDL as 60 mg/dL or above and classifies HDL below 40 mg/dL as a major risk factor for coronary artery disease [4]. In men already at the lower end of normal before starting TRT, a 10 to 15% reduction can push HDL into the high-risk zone. Clinicians should note the absolute starting value, not just the percentage change.

Practically, if a patient's HDL falls below 35 mg/dL on TRT and fails to recover with a dose reduction or switch from IM to transdermal delivery, a statin with demonstrated HDL-raising properties (such as rosuvastatin) or adding niacin supplementation becomes a reasonable adjunct. That decision, however, requires a complete ASCVD risk calculation, not just the HDL value in isolation.

LDL Cholesterol

TRT's effect on LDL is less predictable than its effect on HDL. Some men see a modest decrease in LDL on physiologic-dose testosterone, likely because androgens upregulate hepatic LDL receptors. Others see no change, and a minority see a slight increase, particularly at supraphysiologic serum levels above 1 to 000 ng/dL [5].

The ACC/AHA 2019 guideline on cardiovascular risk reduction sets an LDL threshold of 70 mg/dL for patients with established atherosclerotic cardiovascular disease (ASCVD) and 100 mg/dL for those with a 10-year ASCVD risk of 7.5% or above [6]. TRT patients with pre-existing cardiovascular disease should have LDL measured every 3 months after any dose adjustment, not just annually.

Triglycerides

Triglycerides tend to be the least affected lipid fraction on physiologic TRT. A 2021 systematic review in Frontiers in Endocrinology found no statistically significant change in triglycerides in men receiving testosterone therapy at replacement doses [7]. High-dose or supraphysiologic testosterone use, by contrast, has been associated with hypertriglyceridemia, particularly in men with underlying insulin resistance.

If a patient's triglycerides exceed 500 mg/dL on TRT, the cause is almost certainly dietary or a co-existing metabolic condition rather than the testosterone itself. Investigating fasting glucose, HbA1c, and alcohol use takes priority before attributing the elevation to TRT.

Total Cholesterol

Total cholesterol on TRT generally tracks with the LDL change. It may fall slightly, stay flat, or rise in step with any LDL increase. The total cholesterol number alone is a poor standalone predictor once a patient is on TRT; the ratio of total cholesterol to HDL is more informative. A ratio above 5:1 signals increased cardiovascular risk and should prompt a clinical review of the TRT regimen.

Total Testosterone Range: What You Are Targeting and Why It Affects Lipids

The target serum total testosterone for TRT is not a single number. The Endocrine Society guideline targets the mid-normal range for healthy young men, which is approximately 400 to 700 ng/dL as measured by a morning fasting sample [1]. The American Urological Association 2018 guideline similarly recommends against targeting levels above 1 to 000 ng/dL in replacement-dose patients [8].

Supraphysiologic levels, defined as total testosterone above 1 to 050 ng/dL, are associated with significantly greater HDL suppression and a higher rate of secondary erythrocytosis. Men who self-escalate their TRT dose chasing a "higher is better" total T number often present with the worst lipid panels: HDL below 30 mg/dL, hematocrit above 52%, and elevated LDL. Bringing the total T back into the 400 to 700 ng/dL range over two to three injection cycles typically rescues HDL by 5 to 10 mg/dL without any statin.

Timing of the blood draw relative to the injection also matters. Drawing a trough sample (just before the next injection, typically 6 to 7 days after a weekly IM dose) gives the most reproducible total testosterone number and prevents a falsely elevated peak result from inflating the perceived target attainment.

Free Testosterone Calculation: Why It Matters Alongside the Lipid Panel

Free testosterone is the fraction not bound to sex hormone-binding globulin (SHBG) or albumin. Only about 2 to 3% of circulating testosterone in men is free, yet this fraction is biologically active and drives most of the physiologic effects, including the effects on lipoprotein metabolism [9].

Direct free testosterone immunoassays performed on most commercial platforms are notoriously unreliable, particularly at the lower end of the range. The preferred method is the calculated free testosterone using validated equations (Vermeulen or Ly equations) that require total testosterone, SHBG, and albumin as inputs. Most reference labs offer an SHBG assay; albumin defaults to 4.3 g/dL if not measured.

A calculated free T of 15, 25 pg/mL covers the functional mid-normal range for men aged 30, 55. Men with high SHBG (above 60 nmol/L) can have a total testosterone of 600 ng/dL but a free T below 10 pg/mL, producing persistent hypogonadal symptoms despite apparently adequate total T. In these patients, adjusting dose or switching to a more frequent injection schedule to raise free T can inadvertently push total T supraphysiologic, worsening the lipid panel. Tracking both numbers together prevents that trap.

SHBG itself is affected by TRT: exogenous testosterone tends to suppress SHBG over time, which raises the free fraction even if total T stays constant. This means a patient's lipid-relevant androgenic exposure may be increasing even when the total T on paper looks stable.

Estradiol Sensitive Assay: Reading E2 in the Context of TRT Lipid Monitoring

Estradiol (E2) measured by liquid chromatography-tandem mass spectrometry (LC-MS/MS), often ordered as the "sensitive" or "ultrasensitive" estradiol assay, is a separate but related monitoring marker that connects to lipid health in ways most patients do not expect.

Testosterone aromatizes to estradiol in peripheral adipose tissue, the liver, and the brain. At physiologic levels of estradiol (roughly 20, 40 pg/mL in men), E2 exerts protective effects on the vascular endothelium and has a favorable influence on lipid profiles, specifically by supporting HDL production [10]. This is one reason men should not reflexively suppress estradiol to zero with an aromatase inhibitor (AI) while on TRT.

Men who take anastrozole or letrozole to drive estradiol below 10 pg/mL often see a paradoxical worsening of the lipid panel: HDL falls further and LDL rises, because estrogen-mediated hepatic LDL receptor activity is suppressed. A 2016 study in the Journal of Clinical Endocrinology and Metabolism found that estrogen deprivation in men produced significant increases in LDL and decreases in HDL compared with a testosterone-only control group [10].

The standard immunoassay estradiol (the "regular" E2) is poorly calibrated for male reference ranges and frequently reads falsely elevated due to cross-reactivity with other steroids. Always specify the LC-MS/MS (sensitive) assay when ordering estradiol for male patients on TRT. Target the 20, 40 pg/mL range before deciding whether AI therapy is warranted.

CBC on TRT: The Hematocrit-Lipid Interaction You Cannot Ignore

A complete blood count (CBC) belongs in every TRT monitoring panel for one primary reason: erythrocytosis. Testosterone stimulates erythropoietin production, raising red blood cell mass, hemoglobin, and hematocrit. The FDA label for testosterone products includes a warning about polycythemia, and the Endocrine Society guideline recommends checking hematocrit at 3 to 6 months after initiation and annually thereafter [1].

Hematocrit above 54% is the standard threshold for intervention (dose reduction, switch to a lower-peak delivery method, or therapeutic phlebotomy). At that level, blood viscosity increases in a way that independently raises cardiovascular risk, separate from any lipid change [11]. A patient with HDL of 38 mg/dL and hematocrit of 56% carries compounding vascular risk. Managing both simultaneously, rather than treating each in isolation, is the standard of care.

Phlebotomy, when performed to reduce hematocrit, transiently lowers serum ferritin and can alter the red-cell indices on the CBC. Re-check the CBC 6 to 8 weeks after phlebotomy to confirm response before repeating the lipid panel.

Beyond hematocrit, the CBC on TRT provides:

• Hemoglobin: tracks the magnitude of erythropoiesis stimulation
• MCV (mean corpuscular volume): a persistent MCV above 100 fL suggests B12 or folate deficiency masking the erythrocytosis picture
• Platelet count: rarely affected by TRT but provides a baseline before any potential AI or ancillary medication use
• White blood cell count: TRT has no consistent immunosuppressive or immunostimulating effect at replacement doses, but abnormal values warrant investigation independent of TRT

The TRAVERSE Trial: What the Largest TRT Cardiovascular Safety RCT Found

Concerns about TRT and cardiovascular events reached a peak after a 2013 JAMA paper reported increased adverse events in older men on testosterone gel. TRAVERSE, sponsored by AbbVie and published in the New England Journal of Medicine in 2023, was a randomized, double-blind, placebo-controlled trial specifically powered to assess cardiovascular safety [12].

TRAVERSE enrolled 5,246 men aged 45, 80 with hypogonadism and pre-existing cardiovascular disease or high cardiovascular risk. Participants received testosterone gel 1.62% or placebo for a median follow-up of 22 months. The primary endpoint was major adverse cardiovascular events (MACE): cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke. The trial found non-inferiority of testosterone to placebo on MACE (hazard ratio 0.96 to 96.08% CI 0.78, 1.17; P<0.001 for non-inferiority) [12].

The Endocrine Society's official statement on TRAVERSE noted: "These findings provide reassurance that testosterone therapy at replacement doses does not substantially increase the risk of major cardiovascular events in hypogonadal men over approximately two years of follow-up" [1].

What TRAVERSE did not evaluate: the lipid effects of supraphysiologic testosterone, the use of injectable testosterone cypionate (the most commonly prescribed TRT formulation in the United States), or long-term follow-up beyond 22 months. Clinicians should not use TRAVERSE as a blanket clearance for aggressive TRT dosing, particularly in patients with existing dyslipidemia.

How to Interpret Your Full TRT Lab Panel Together

A lipid panel read in isolation misses the clinical picture. The full TRT monitoring panel covers six interconnected domains, and each result informs the interpretation of the others.

Total testosterone (trough) establishes whether you are in a replacement or supraphysiologic range. If total T exceeds 1 to 000 ng/dL at trough, any lipid abnormality is almost certainly dose-driven.

Free testosterone (calculated) confirms that biologically active androgen exposure matches the total T. Unexpectedly low free T despite a normal total T points to high SHBG and guides dose or formulation changes.

Estradiol (LC-MS/MS) rules out aromatase inhibitor overuse as a driver of lipid worsening. If E2 falls below 15 pg/mL and the lipid panel is deteriorating, the AI is likely contributing.

CBC with hematocrit adds a vascular risk dimension that the lipid panel alone cannot capture. Hematocrit above 54% doubles down on cardiovascular risk in any patient with an HDL below 40 mg/dL.

PSA is not a lipid marker, but it belongs on the same draw date to minimize patient burden and ensure the full cardiovascular and hormonal safety picture is reviewed in one clinical encounter.

Metabolic panel (CMP) including fasting glucose and liver enzymes rounds out the picture. Elevated liver enzymes on TRT (AST, ALT above three times the upper limit of normal) warrant investigation for hepatotoxicity, especially with oral or compounded preparations.

Practical Dosing Adjustments Driven by Lipid Results

When HDL drops below 35 mg/dL on TRT, the first move is a dose reduction, not a statin. Reducing testosterone cypionate from 200 mg/week to 140 mg/week typically recovers 4 to 8 mg/dL of HDL over 8 to 12 weeks without meaningfully reducing symptomatic testosterone benefit, provided free T remains above 12 pg/mL.

If switching from weekly IM injections to twice-weekly injections at half the dose per injection, peak testosterone levels fall by roughly 30 to 40%, which blunts hepatic lipase stimulation and can raise HDL by a clinically meaningful 3 to 6 mg/dL. This regimen change, moving from 200 mg every 7 days to 100 mg every 3.5 days, is often the simplest intervention before considering a lipid-lowering drug.

Transdermal testosterone (1% gel, 50 to 100 mg/day applied to the shoulder or upper arm) maintains more stable serum testosterone levels and causes less HDL suppression than equivalent-dose weekly IM therapy. The tradeoff is lower absolute testosterone delivery and a higher rate of application-site skin irritation, but for patients with cardiovascular risk and borderline HDL, the cardiovascular profile of the transdermal route is preferable.

For patients whose LDL exceeds 130 mg/dL and whose 10-year ASCVD risk (calculated using the AHA Pooled Cohort Equations) exceeds 7.5%, initiating rosuvastatin 10 to 20 mg/day is appropriate. Rosuvastatin has the best evidence base for LDL reduction and a neutral to mildly favorable effect on HDL among the statin class [6].

Building a Monitoring Schedule That Catches Problems Early

The following schedule reflects Endocrine Society guideline recommendations plus practical clinical judgment from management of patients on ongoing TRT [1]:

Before starting TRT: Fasting lipid panel, total testosterone (morning, fasting), SHBG, calculated free T, sensitive estradiol (LC-MS/MS), CBC with differential, CMP, PSA (for men above 40).

3 months after initiating TRT or changing dose: Total testosterone (trough), CBC with hematocrit, sensitive estradiol. Repeat lipid panel only if baseline showed abnormalities or if the dose change was greater than 20%.

6 months after initiating TRT: Full panel including fasting lipid panel, total testosterone (trough), SHBG, calculated free T, sensitive estradiol, CBC, CMP, PSA.

Annual maintenance (after levels are stable): Fasting lipid panel, total testosterone (trough), CBC with hematocrit, sensitive estradiol, PSA, CMP.

Any single hematocrit above 54%, HDL below 30 mg/dL, or LDL above 160 mg/dL triggers an out-of-cycle visit and dose review rather than waiting for the next scheduled lab draw.